subject: Cardiac Injuries Prompt Louisiana Residents to File Darvocet Lawsuit [print this page] Cardiac Injuries Prompt Louisiana Residents to File Darvocet Lawsuit
Three Louisiana residents filed a Darvocet lawsuit recently against several drug manufacturers, claiming that the painkiller caused them to suffer cardiac injuries.
On March 4, Billy Lambert, Gladys Delaune, and Margaret Seagraves filed suit in U.S. District Court for the Eastern District of Louisiana. The complaint names several defendants that either currently manufacture or previously manufactured Darvocet, including Xanodyne Pharmaceuticals, AAIPharma Services, Eli Lilly and Company, Teva Pharmaceuticals USA, and Qualitest Pharmaceuticals. The lawsuit alleges that Darvocet caused the plaintiffs to develop serious, life-threatening heart conditions, including wide complex tachycardia, a type of cardiac rhythm abnormality. The principal charge against the defendants is that they knew or reasonably should have known about Darvocet's potential health risks and failed to warn the public about them.
By taking legal action against the pharmaceutical companies that make or previously made Darvocet available to the public, the Louisiana plaintiffs join dozens of others nationwide who similarly accuse drug makers of producing and failing to warn about a dangerous product. Darvocet, along with Darvon and a host of generic pain relievers containing the drug propoxyphene, were recalled last year by the U.S. Food and Drug Administration (FDA). Eli Lilly and Company originally developed Darvon (in 1957) and Darvocet (in 1972) before selling the drugs to AAIPharma in 2002. Current distributor Xanodyne Pharmaceuticals acquired the rights to Darvon and Darvocet in 2005 after AAI became insolvent. Propoxyphene is generically manufactured by a number of companies, including Teva and Qualitest.
A hearing is scheduled for the end of this month to determine whether all Darvon and Darvocet lawsuits should be consolidated under a single judge for pretrial proceedings. So-called Multidistrict Litigation (MDL) would allow all the parties involved with propoxyphene litigation to save significant time and resources.
Following the March 30 MDL hearing in San Diego, the Rottenstein Law Group will provide all the details of this important development. Until then, you can contact RLG about any question you have concerning the recalled drug propoxyphene, or to initiate a Darvocet Lawsuits. You have limited time to file a claim, so it is important that you act quickly. RLG's lawyers have more than 25 years of experience in product liability law. By choosing us to handle your case, you are selecting legal professionals who are dedicated to obtaining the best possible results.
welcome to Insurances.net (https://www.insurances.net)
